Bladder Cancer
Showing NaN - NaN of 51
NSCLC, Gastric Carcinoma, Gastroesophageal Junction Carcinoma Trial in Worldwide (SEA-TGT, sasanlimab)
Recruiting
- Non-small Cell Lung Cancer
- +11 more
-
Birmingham, Alabama
- +32 more
Jan 4, 2023
Melanoma, NSCLC, Bladder Cancer Trial in Worldwide (Autogene cevumeran, Atezolizumab)
Active, not recruiting
- Melanoma
- +7 more
- Autogene cevumeran
- Atezolizumab
-
Scottsdale, Arizona
- +36 more
Dec 22, 2022
Bladder Cancer Trial in Worldwide (Atezolizumab)
Active, not recruiting
- Bladder Cancer
-
Birmingham, Alabama
- +76 more
Dec 6, 2022
Bladder Cancer Trial in Worldwide (Atezolizumab)
Active, not recruiting
- Bladder Cancer
-
Birmingham, Alabama
- +76 more
Dec 6, 2022
Intravesical Therapy and Surgery as Treatment Options for
Recruiting
- Bladder Cancer
- +2 more
-
Birmingham, Alabama
- +37 more
Nov 28, 2022
Validation for Early Cancer Detection and Minimal Residual
Recruiting
- Brain Cancer
- +19 more
-
Duarte, California
- +6 more
Nov 10, 2022
Urothelial Carcinoma, Bladder Cancer Trial in United States (Placebo, Pembrolizumab)
Completed
- Urothelial Carcinoma
- Bladder Cancer
- Placebo
- Pembrolizumab
-
Phoenix, Arizona
- +27 more
Sep 16, 2022
Metastatic Cancer, Solid Tumors, Colorectal Cancer (CRC) Trial in Worldwide (INCB001158, Pembrolizumab)
Active, not recruiting
- Metastatic Cancer
- +9 more
-
Mobile, Alabama
- +19 more
Aug 1, 2022
NSCLC, Renal Cell Cancer, Colorectal Cancer Trial in Australia, United States (CPI-006, CPI-006 + ciforadenant, CPI-006 +
Active, not recruiting
- Non-Small Cell Lung Cancer
- +12 more
- CPI-006
- +2 more
-
Tucson, Arizona
- +26 more
Aug 1, 2022
Oncology, Melanoma, Ovarian Cancer Trial in United States (E-602, Pembrolizumab)
Recruiting
- Oncology
- +16 more
- E-602
- Pembrolizumab
-
Grand Rapids, Michigan
- +4 more
May 27, 2022
Advanced Solid Tumors With Literature Evidence of CD25(+) Treg Content, Head Neck Cancer Squamous Cell Carcinoma, NSCLC Trial in
Recruiting
- Advanced Solid Tumors With Literature Evidence of CD25(+) Treg Content
- +12 more
- ADCT-301
- Pembrolizumab
-
Palo Alto, California
- +9 more
Mar 24, 2022
Bladder Cancer, Urothelial Carcinoma, Solid Tumor Trial in Worldwide (IPI-549 (eganelisib), Nivolumab, Placebos)
Active, not recruiting
- Bladder Cancer
- +3 more
- IPI-549 (eganelisib)
- +2 more
-
Fort Wayne, Indiana
- +28 more
Apr 1, 2022
Prostate Cancer, Melanoma, Renal Cell Carcinoma Trial in United States (MGA271)
Completed
- Prostate Cancer
- +6 more
- MGA271
-
Los Angeles, California
- +11 more
Feb 4, 2022
Mesothelioma, Bladder Cancer, Melanoma Trial in Australia, Canada, United States (MGD009)
Terminated
- Mesothelioma
- +12 more
- MGD009
-
Los Angeles, California
- +19 more
Feb 4, 2022
Urothelial Carcinoma, Urothelial Carcinoma Bladder, Bladder Cancer Trial in United States (IK-175, IK-175 and nivolumab)
Recruiting
- Urothelial Carcinoma
- +20 more
- IK-175
- IK-175 and nivolumab
-
Gilbert, Arizona
- +9 more
Feb 3, 2022
HER2-positive, Adenocarcinoma, Bile Duct Cancer Trial in United States (CT-0508)
Recruiting
- HER2-positive
- +30 more
- CT-0508
-
Duarte, California
- +4 more
Feb 1, 2022
Urothelial Carcinoma, Bladder Cancer, Transitional Cell Carcinoma Trial in United States (nab-paclitaxel, Gemcitabine)
Terminated
- Urothelial Carcinoma
- +2 more
-
Fort Myers, Florida
- +4 more
Dec 15, 2021
Bladder Cancer Trial in United States (Gemcitabine, Cisplatin, Methotrexate)
Ovary Cancer, Cervix Cancer, Endometrium Cancer Trial in Worldwide (Tisotumab Vedotin (HuMax-TF-ADC))
Completed
- Ovary Cancer
- +7 more
- Tisotumab Vedotin (HuMax-TF-ADC)
-
Orange, California
- +28 more
Nov 29, 2021
Colorectal Cancer Metastatic, Triple Negative Breast Cancer, Non Small Cell Lung Cancer Trial in Canada, United States (EDP1503,
Completed
- Colorectal Cancer Metastatic
- +6 more
- EDP1503
- Pembrolizumab
-
Rogers, Arkansas
- +7 more
Nov 11, 2021